La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California. La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus, and was being considered as a treatment for other autoimmune disorders. However, the company ceased most of its operations after trials of Riquent failed in 2009. Adamis Pharmaceuticals has announced it intends to acquire La Jolla Pharmaceuticals.

Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

Galderma Laboratories, L.P., a dermatology company, engages in the research, development, and marketing of dermatology products. Its pharmaceutical and over-the-counter products include Differin, which is used to treat acne; MetroGel, MetroLotion, and MetroCream, to treat rosacea; Clobex lotion, which helps in controlling and treating moderate-to-severe plaque psoriasis; and Cetaphil, a line of cleansers and moisturizers. The company has operations in North America, Western Europe, Latin America, Asia, Australia, and Africa. It offers its services directly, and through sales representatives, as well as through special programs. The company was founded in 1961 as Owen Laboratories and changed its name to Galderma Laboratories, L.P. in 1981. The company is headquartered in Fort Worth, Texas. Galderma Laboratories, L.P. operates as a subsidiary of Galderma SA.

Fornix was established in 1999 after a reverse takeover of Dr. Fisher Farma B.V. by Artu Biologicals. Fornix BioSciences has joined the draft in the war against allergies. The Dutch company develops diagnostic and immunotherapeutic allergen products and medical aids. Its allergy division develops and markets sublingual (under the tongue) allergen aids to human and animal patients, particularly dogs, throughout Europe. The company's trading division, Dr. Fisher Farma, imports and distributes a variety of patented drugs, while its Medical Aids division focuses on the sale of medical aids and medical and nursing disposables.

Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Roche Colorado is one of the research, development, and manufacturing facilities of pharmaceutical giant Roche. Its R&D operations focus on developing efficient and high-quality production processes for manufacturing pharmaceutical ingredients and compounds. It has worked to bring to market such drugs as the anti-HIV treatments Fuzeon and Invirase and the influenza drug Tamiflu. Roche Colorado company also provides contract manufacturing of peptides, a protein-like compound used in pharmaceuticals. Roche Colorado is one of several US-based research and production facilities owned by Roche; affiliates include Hoffman-La Roche and Genentech.

Oragenics, Inc. company was founded in 1996 and is based in Alachua, Florida. Oragenics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of products and technologies associated with oral health, antibiotics, and other general health benefits. The company develops Probiora3, an oral probiotics technology that employs three natural strains of beneficial bacteria, which promote oral health; LPT3-04 for weight loss; and DPOLT or differentially protected orthogonal lantionine technology, which is a solid or liquid phase peptide synthesis platform technology that has various applications for the manufacture of commercially important bioactive peptides. It is also developing Mutacin 1140, an antibiotic with antimicrobial activity against gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus; Proteomic-based In-Vivo Induced Antigen Technology (PIVIAT) and Proteomic-based Change Mediated Antigen Technology (PCMAT) diagnostic platforms that enable the identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers, and other diseases in humans and other living organisms, including plants; and SMaRT Replacement Therapy, which is a painless topical treatment for protection against tooth decay. The company primarily operates in the United States and Mexico. It was formerly known as Oragen, Inc.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on the areas of serious unmet medical need, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer's disease. Its lead products include cardiovascular medicines, including PLAVIX and AVAPRO/AVALIDE; ABILIFY, a medicine for the treatment of mental illness; ERBITUX, SPRYCEL, and IXEMPRA, which are cancer medicines; HIV medicines, such as REYATAZ, SUSTIVA, and ATRIPLA; BARACLUDE, a medicine for hepatitis B; ONGLYZA, a type 2 diabetes treatment; and ORENCIA, a medicine for rheumatoid arthritis. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, dapagliflozin, ipilimumab, belatacept, and brivanib. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer, Inc.; and various biotech companies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.